Searched for
ALEMBIC PHARMA NET PROFIT
Should long term investors bet on Waterways Leisure IPO?Ocean cruise operator Waterways Leisure Tourism is set to raise ₹585 crore for expansion and lease payments. Despite operating a single ves...- KSIIDC pays Rs 143 crore dividend to Karnataka govt; FY25 profit at Rs 188 crore: MB PatilKarnataka State Industrial and Infrastructure Development Corporation (KSIIDC) has presented a dividend exceeding Rs 143 crore to the state...
- Cochin Shipyard shares fall 3% amid buzz around OFS at 8% discountCochin Shipyard shares dipped Monday following reports of a potential government Offer for Sale (OFS) at a discount. The government, aiming...
- Tata Capital shares slip 3% after stock rallies 17% in one week to lifetime high. What’s ahead?Tata Capital shares saw a dip on Monday following a significant rally that propelled them to an all-time high last week. Despite a recent s...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Power sector stocks regain momentum on rising electricity demand and strong investment cycleRising electricity demand and a strong investment cycle lift outlook for power companies.
- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
- India bans 16 fixed-dose drug combinations over safety concernsIn a significant public health initiative, the ban on 16 fixed-dose drug combinations, including various antibiotics and topical formulatio...
- Leader's Premium: The math behind Jio Platforms' priceJio Platforms' upcoming IPO is priced at a premium, reflecting its market leadership and advanced 4G/5G network. Despite smaller revenues t...
- Alembic Pharma gets tentative nod from USFDA for generic cancer drugAlembic Pharmaceuticals has secured tentative approval from the USFDA for its generic Binimetinib tablets. This marks a significant step fo...
- L’Oréal adds Innovist to cart; HealthQuad's new fundHappy Friday! Personal care giant L’Oreal has acquired a majority stake in Innovist in India’s biggest D2C deal. This and more in today’s E...
- Growth over scale: NSE is priced at a discount to BSENSE's upcoming IPO is set for a discount compared to its peer BSE. This valuation reflects slower growth in NSE's core business. BSE, howev...
- Despite West Asia crisis, net direct tax mopup grows 15% to Rs 5.2 lakh croreIndia's direct tax collections have seen a significant rise of over 14 percent. This growth is driven by strong advance tax payments from c...
- Dhan parent Raise Securities posts Rs 905 crore revenue, profit down 20% in FY26The company had reported net operating income of Rs 795 crore and a profit after tax of Rs 408 crore in FY25. The rating agency attributed ...
- Redington shares rally 10% after Apple CEO Tim Cook says price hikes 'unavoidable' amid AI boomRedington shares surged over 10% after Apple CEO Tim Cook signalled potential price hikes due to rising memory and storage costs driven by ...
- Liotech Industries IPO opens for subscription today. Check GMP, price band and other detailsLiotech Industries has fixed the issue price at Rs 321 per share. The IPO is a combination of a fresh issue of 9 lakh shares aggregating Rs...
- Tata Sons' chairman N Chandrasekaran declines pay hike amid group concernsTata Sons chairman N. Chandrasekaran will not seek a pay raise for FY26. This decision comes amid group concerns about capital allocation a...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
Load More
